Oliver Surriga

About Oliver Surriga

Oliver Surriga, With an exceptional h-index of 6 and a recent h-index of 6 (since 2020), a distinguished researcher at Columbia University in the City of New York, specializes in the field of Oncology.

His recent articles reflect a diverse array of research interests and contributions to the field:

Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

A biparatopic antibody–drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Oliver Surriga Information

University

Position

___

Citations(all)

410

Citations(since 2020)

233

Cited By

276

hIndex(all)

6

hIndex(since 2020)

6

i10Index(all)

6

i10Index(since 2020)

5

Email

University Profile Page

Google Scholar

Oliver Surriga Skills & Research Interests

Oncology

Top articles of Oliver Surriga

Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met

2022/2/10

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

Frontiers in oncology

2022/8/29

A biparatopic antibody–drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade

Molecular Cancer Therapeutics

2021/10/1

Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target

Melanoma research

2021/2/1

See List of Professors in Oliver Surriga University(Columbia University in the City of New York)